Pregnant and Taking Gabapentin? Here Is What the Evidence Actually Says

Few decisions feel more consequential than choosing a medication during pregnancy. When gabapentin — a drug prescribed for conditions ranging from epilepsy to diabetic neuropathy to anxiety disorders — is already part of a patient's treatment plan, discovering a pregnancy can trigger immediate concern. Is the medication harming the developing baby? Should it be stopped immediately? Are there safer options?

These are not simple questions, and the answers depend heavily on individual circumstances. What follows is a thorough examination of what science and clinical practice currently tell us about gabapentin use during pregnancy.

Where Gabapentin Stands with the FDA

Gabapentin carries an FDA Pregnancy Category C designation — a classification that was part of the older labeling system used before 2015. Category C means that animal studies have shown adverse fetal effects, but there are insufficient well-controlled human studies to draw definitive conclusions. The benefit of the medication may still justify use in some cases, but the designation signals caution rather than clearance.

Under the current FDA labeling system, which replaced the letter categories, gabapentin's prescribing information acknowledges that available data from pregnancy registries and observational studies are limited and cannot reliably establish or rule out drug-associated risk. This measured language reflects genuine scientific uncertainty — not reassurance.

What Research Has Found About Fetal Exposure

Gabapentin does cross the placental barrier. Studies using cord blood samples have confirmed that the drug reaches the fetus, sometimes at concentrations comparable to maternal blood levels. This biological reality makes the question of fetal impact more than theoretical.

Several large observational studies and registry analyses have attempted to characterize the risks. Some findings have raised concern:

• Preterm birth: Multiple studies, including a frequently cited analysis published in Neurology, have identified an association between gabapentin use during pregnancy and increased rates of preterm delivery. The association was particularly notable in women who used the drug during the third trimester.
• Low birth weight and NICU admission: Some data suggest neonates born to mothers who took gabapentin are more likely to require neonatal intensive care unit admission, though it remains difficult to fully disentangle the effects of the drug from those of the underlying condition being treated.
• Neonatal withdrawal: Newborns exposed to gabapentin in utero may exhibit withdrawal-like symptoms after birth, including jitteriness, feeding difficulties, and respiratory changes. Neonatal care teams in US hospitals have become increasingly attentive to this possibility.
• Structural birth defects: Evidence here is less consistent. Some studies have suggested a modest increase in certain congenital anomalies, while others have not replicated this finding. The data are not strong enough to establish a definitive causal link.

It is important to note that most studies in this area have significant methodological limitations. Pregnant women who take gabapentin often have serious underlying conditions — epilepsy, fibromyalgia, postherpetic neuralgia — that themselves carry pregnancy risks. Separating the drug's effect from the disease's effect is extraordinarily difficult.

How Physicians Weigh the Decision

No responsible clinician will issue a blanket recommendation to continue or discontinue gabapentin during pregnancy without considering the full clinical picture. The risk-benefit analysis varies considerably depending on why the medication was prescribed.

For epilepsy: Uncontrolled seizures during pregnancy pose documented dangers to both mother and fetus, including risk of falls, trauma, hypoxia, and pregnancy loss. In this context, the risks of stopping an effective seizure medication may outweigh the risks of continued use. Neurologists and maternal-fetal medicine specialists typically work together to determine the safest approach.

For nerve pain: Conditions such as diabetic neuropathy or postherpetic neuralgia can cause severe, debilitating pain. While suffering is never trivial, pain conditions generally allow more flexibility in exploring alternative treatments than epilepsy does.

For off-label uses such as anxiety or insomnia: These indications warrant particular scrutiny during pregnancy. The risk-benefit equation is harder to justify when safer, better-studied alternatives may be available.

Women who become pregnant while taking gabapentin should not stop the medication abruptly without medical guidance — particularly if it is controlling seizures. Sudden discontinuation carries its own set of risks, which are addressed in detail elsewhere on this site.

Safer Alternatives Worth Discussing with Your Provider

Depending on the condition being treated, several alternatives have more established safety profiles in pregnancy:

• For nerve pain: Acetaminophen remains the most widely recommended analgesic for mild to moderate pain during pregnancy. Certain topical treatments, physical therapy, and nerve blocks may also be considered. Tricyclic antidepressants like nortriptyline have more pregnancy data than gabapentin, though they are not risk-free either.
• For seizures: Lamotrigine is generally considered to have a more favorable pregnancy safety profile among antiseizure medications and is often preferred when a medication switch is feasible.
• For anxiety: Cognitive behavioral therapy (CBT) is a first-line, evidence-based treatment for anxiety disorders during pregnancy and carries no medication-related fetal risk. Certain SSRIs have more robust pregnancy safety data than gabapentin, though all psychiatric medications require careful evaluation.
• For sleep difficulties: Sleep hygiene interventions, CBT for insomnia (CBT-I), and careful evaluation of underlying causes are preferable to pharmacologic management during pregnancy.

None of these alternatives is universally superior in every situation. Any medication change during pregnancy should be coordinated with a healthcare provider, ideally one with expertise in maternal-fetal medicine or the relevant specialty.

Practical Steps for Pregnant Patients

If you are pregnant or planning to become pregnant and currently take gabapentin, the following steps are worth discussing with your care team:

1. Do not stop abruptly. Even if you are concerned, stopping gabapentin without guidance can cause rebound symptoms or, in the case of seizure disorders, dangerous withdrawal effects.
2. Request a specialist consultation. A maternal-fetal medicine specialist can help assess your individual risk profile and coordinate care across specialties.
3. Enroll in a pregnancy registry. The North American Antiepileptic Drug (NAAED) Pregnancy Registry collects data on medication-exposed pregnancies and can provide you with updated safety information. Participation also contributes to research that benefits future patients.
4. Document your medication history. Your obstetric team and neonatal care providers should know about gabapentin exposure so they can monitor your newborn appropriately.
5. Ask about the lowest effective dose. If continuation is deemed necessary, minimizing dose exposure — particularly during the first trimester when organogenesis occurs — is a reasonable clinical goal.

The Importance of Individualized Care

Pregnancy amplifies the stakes of every medical decision. The honest answer to the question "Is gabapentin safe during pregnancy?" is that the evidence is incomplete, the risks appear real but incompletely characterized, and the right choice depends on factors unique to each patient.

What the evidence does support clearly is this: informed, shared decision-making between a pregnant patient and her healthcare team — ideally including specialists — produces better outcomes than either reflexive discontinuation or uncritical continuation. Women deserve complete information and a care team willing to engage seriously with these difficult questions.

Gabapentin Guide encourages all patients to use this content as a starting point for conversation with their providers, not as a substitute for personalized medical advice.